午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Inhibitors>TGF-beta / Smad>TGF-beta / Smad inhibitors>ML347
ML347
  • ML347

ML347 NEW

Price $52 $77 $159
Package 5mg 10mg 25mg
Min. Order:
Supply Ability: 10g
Update Time: 2025-07-07

Product Details

Product Name: ML347 CAS No.: 1062368-49-3
Purity: 98.3% Supply Ability: 10g
Release date: 2025/07/07

Product Introduction

Bioactivity

NameML347
DescriptionML347 (LDN 193719)(DN193719) is a highly specific ALK1/2 inhibitor ( IC50: 46/32 nM), and the selectivity for ALK2 is >300-fold than ALK3.
Kinase AssayKinase assay: All kinase assays are conducted by Reaction Biology Corp. In brief, compounds are tested at 10 concentrations by 3-fold serial dilutions starting at 30 μM, using nonspecific kinase inhibitor staurosporine as control. In vitro kinase reactions are carried out in the presence of 10 μM (33P)γATP. Five kinases tested are the human BMP type-I receptor activin receptor-like kinase 2 (ALK-2/ACVR1), the human TGFβ type-I receptor activin receptor-like kinase 5 (Alk5/TGFβR1), the human VEGF type-II receptor (KDR/Flk-1/VEGFR2), the human AMP-activated protein kinase (AMPK/A1/B1/G1) and the human platelet-derived growth factor receptor-β (PDGFRβ).
In vivoIn both human and rat plasma, ML347 exhibits high binding affinity with plasma proteins. Additionally, ML347 demonstrates significant efficacy in C2C12BRA cells responsive to BMP signaling, evidenced by an IC50 value of 15 nM.
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility InformationDMSO : 1 mg/mL (2.84 mM), Sonication is recommended.
KeywordsTransforming growth factor beta receptors | TGF-β/Smad | TGF-β Receptor | TGFβ | TGFbeta/Smad | TGF-beta | TGFbeta | TGF-b/Smad | TGFb | Smad1/5 | Smad | ML-347 | ML347 | ML 347 | LDN-193719 | LDN193719 | Inhibitor | inhibit | ALK6 | ALK3 | ALK2 | ALK1
Inhibitors RelatedEntrectinib | Monocrotaline | DMH-1 | Hydrochlorothiazide | Chebulinic acid | Crizotinib | Chromenone 1 | Ceritinib | Pirfenidone | A 83-01 | Galunisertib | Alantolactone
Related Compound LibrariesHighly Selective Inhibitor Library | Reprogramming Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | TGF-beta/Smad Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$/
Anhui Ruihan Technology Co., Ltd
2023-08-21
  • Since: 2011-01-07
  • Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY